{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:21:27Z","timestamp":1762507287625},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.yrtph.2017.12.015","type":"journal-article","created":{"date-parts":[[2017,12,24]],"date-time":"2017-12-24T01:32:08Z","timestamp":1514079128000},"page":"382-389","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Carcinogenicity assessment of the Hedgehog pathway inhibitor, vismodegib in Tg.rasH2 mice and Sprague-Dawley rats"],"prefix":"10.1016","volume":"92","author":[{"given":"Jinze","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Morinello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denzil","family":"Frost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivor","family":"Caro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Gould","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Hendricks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noel","family":"Dybdal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Dambach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Schutten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2017.12.015_bib1","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/jamadermatol.2013.1798","article-title":"New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases","volume":"149","author":"Aasi","year":"2013","journal-title":"JAMA Dermatol."},{"issue":"6","key":"10.1016\/j.yrtph.2017.12.015_bib2","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.ctrv.2014.02.003","article-title":"Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer","volume":"40","author":"Brechniel","year":"2014","journal-title":"Canc. Treat Rep."},{"key":"10.1016\/j.yrtph.2017.12.015_bib3","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/7747","article-title":"A common human skin tumor is caused by activating mutations in beta-catenin","volume":"21","author":"Chan","year":"1999","journal-title":"Nat. Genet."},{"key":"10.1016\/j.yrtph.2017.12.015_bib4","series-title":"Statistical Aspects of the Design, Analysis, and Interpretation of Chronic Rodent Carcinogenicity Studies of Pharmaceuticals","author":"FDA Draft Guidance for Industry","year":"2001"},{"key":"10.1016\/j.yrtph.2017.12.015_bib5","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0092-8674(00)81631-1","article-title":"De novo hair follicle morphogenesis and hair tumors in mice expressing a truncated \u03b2-catenin in skin","volume":"95","author":"Gat","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.yrtph.2017.12.015_bib6","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/1097-0142(199007\/08)14:4<801::AID-CNCR2820140417>3.0.CO;2-K","article-title":"The role of the hair follicle in the origin and evolution of some cutaneous neoplasms of man and experimental animals","volume":"14","author":"Ghadially","year":"1961","journal-title":"Cancer"},{"key":"10.1016\/j.yrtph.2017.12.015_bib7","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jamaophthalmol.2013.5018","article-title":"Vismodegib for periocular and orbital basal cell carcinoma","volume":"13","author":"Gill","year":"2013","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.yrtph.2017.12.015_bib8","series-title":"Histopathology of Preclinical Toxicity Studies","author":"Greaves","year":"2012"},{"key":"10.1016\/j.yrtph.2017.12.015_bib9","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1309\/EALEG7LD6W7167PX","article-title":"\u03b2-catenin is expressed aberrantly in tumors expressing shadow cells","volume":"120","author":"Hassanein","year":"2003","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.yrtph.2017.12.015_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2013.01.023","article-title":"Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib","volume":"69","author":"Iarrobino","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.yrtph.2017.12.015_bib11","unstructured":"ICH S1. Proposed Change to Rodent Carcinogenicity Testing of Pharmaceuticals - Regulatory Notice for Public Input."},{"key":"10.1016\/j.yrtph.2017.12.015_bib12","series-title":"Nonclinical Evaluation of Anticancer Pharmaceuticals","author":"ICH S9","year":"2010"},{"key":"10.1016\/j.yrtph.2017.12.015_bib13","doi-asserted-by":"crossref","first-page":"759","DOI":"10.5858\/arpa.2013-0157-RA","article-title":"Molecular pathology of skin neoplasms of the head and neck","volume":"138","author":"Kraft","year":"2014","journal-title":"Arch. Pathol. Lab Med."},{"key":"10.1016\/j.yrtph.2017.12.015_bib14","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1158\/1055-9965.EPI-10-0243","article-title":"Nonmelanoma skin cancer and the risk of second primary cancers: a systematic review","volume":"19","author":"Lee","year":"2010","journal-title":"Canc. Epidemiol. Biomarkers Prev."},{"issue":"7","key":"10.1016\/j.yrtph.2017.12.015_bib15","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1177\/0192623310382557","article-title":"Hematopoietic proliferative lesions in the spleen of rasH2 transgenic mice treated with MNU","volume":"38","author":"Long","year":"2010","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.yrtph.2017.12.015_bib16","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1001\/archderm.136.12.1524","article-title":"Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis","volume":"136","author":"Marcil","year":"2000","journal-title":"Arch. Dermatol."},{"issue":"2","key":"10.1016\/j.yrtph.2017.12.015_bib17","first-page":"283","article-title":"Guidelines for combining neoplasms for evaluation of rodent carcinogenicity studies","volume":"76","author":"McConnell","year":"1986","journal-title":"J. Nat. Canc. Inst."},{"key":"10.1016\/j.yrtph.2017.12.015_bib18","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jamadermatol.2015.4330","article-title":"Increased risk of cutaneous SCC after vismodegib therapy for BCC","volume":"152","author":"Mohan","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.yrtph.2017.12.015_bib19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/01926230252824851","article-title":"The Tg rasH2 mouse in cancer hazard identification","volume":"30","author":"Morton","year":"2002","journal-title":"Toxicol. Pathol."},{"issue":"4","key":"10.1016\/j.yrtph.2017.12.015_bib20","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1177\/0192623311436181","article-title":"Spontaneous tumor incidence in rasH2 mice: review of internal data and published literature","volume":"40","author":"Nambiar","year":"2012","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.yrtph.2017.12.015_bib21","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/bjd.12840","article-title":"Multiple highly and moderately differentiated squamous cell carcinomas of the skin during vismodegib treatment of inoperable basal cell carcinoma","volume":"171","author":"Orouji","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.yrtph.2017.12.015_bib22","article-title":"Cooperative integration between hedgehog-Gli signaling and other oncogenic pathways: implications for cancer therapy","volume":"17","author":"Pandolfi","year":"2015","journal-title":"Expet Rev. Mol. Med."},{"key":"10.1016\/j.yrtph.2017.12.015_bib23","first-page":"311","article-title":"Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments","author":"Peto","year":"1980","journal-title":"IARC Monogr. Eval. Carcinog. Risk Chem. Humans \u2013 Suppl."},{"key":"10.1016\/j.yrtph.2017.12.015_bib24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000368350","article-title":"Fast-growing cutaneous squamous cell carcinoma in a patient treated with vismodegib","volume":"230","author":"Poulalhon","year":"2015","journal-title":"Dermatology"},{"key":"10.1016\/j.yrtph.2017.12.015_bib25","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1468-3083.2012.04483.x","article-title":"Host risk factors for the development of multiple non-melanoma skin cancers","volume":"27","author":"Qureshi","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.yrtph.2017.12.015_bib26","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/modpathol.2015.5","article-title":"Keratoacanthoma and squamous cell carcinoma are distinct from a molecular perspective","volume":"28","author":"Ra","year":"2015","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.yrtph.2017.12.015_bib27","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMc1504261","article-title":"Squamous change in basal cell carcinoma with drug resistance","volume":"373","author":"Ransohoff","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yrtph.2017.12.015_bib28","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/jdv.12526","article-title":"Development of squamous cell carcinoma into basal cell carcinoma under treatment with Vismodegib","volume":"29","author":"Saintes","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.yrtph.2017.12.015_bib29","series-title":"Statistical Analysis System. Version 9.2","author":"SAS","year":"2002"},{"key":"10.1016\/j.yrtph.2017.12.015_bib30","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.tips.2009.03.007","article-title":"Mechanisms of Hedgehog pathway activation in cancer and implications for therapy","volume":"30","author":"Scales","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"issue":"23","key":"10.1016\/j.yrtph.2017.12.015_bib31","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","author":"Sekulic","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yrtph.2017.12.015_bib32","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s12885-017-3286-5","article-title":"Long term safety and efficacy of vismodegib patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study","volume":"17","author":"Sekulic","year":"2017","journal-title":"BMC Canc."},{"issue":"1","key":"10.1016\/j.yrtph.2017.12.015_bib33","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaad.2015.03.013","article-title":"A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma","volume":"73","author":"Sofen","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.yrtph.2017.12.015_bib34","first-page":"191","article-title":"Interlaboratory comparison of short-term carcinogenicity studies using CB6F1-rasH2 transgenic mice","volume":"31","author":"Takaoka","year":"2003","journal-title":"Toxicol. Pathol."},{"issue":"2\u20133","key":"10.1016\/j.yrtph.2017.12.015_bib35","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0010-468X(85)90015-7","article-title":"A FORTRAN program for testing trend and Homogeneity in proportions","volume":"19","author":"Thakur","year":"1985","journal-title":"Comput. Progr. Biomed."},{"key":"10.1016\/j.yrtph.2017.12.015_bib36","first-page":"713","article-title":"Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib","author":"Tina","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.yrtph.2017.12.015_bib37","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1158\/1078-0432.CCR-11-0975","article-title":"Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent hedgehog pathway activation","volume":"17","author":"Wong","year":"2011","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.yrtph.2017.12.015_bib38","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nature07275","article-title":"A paracrine requirement for Hedgehog signalling in cancer","volume":"455","author":"Yauch","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.yrtph.2017.12.015_bib39","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jamadermatol.2014.583","article-title":"Two different scenarios of squamous cell carcinoma within advanced basal cell carcinomas. cases illustrating the importance of serial biopsy during vismodegib usage","volume":"150","author":"Zhu","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.yrtph.2017.12.015_bib40","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/019262339202000303","article-title":"Spontaneous skin neoplasms in aged Sprague-dawley rats","volume":"20","author":"Zwicker","year":"1992","journal-title":"Tox Path"}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230017304026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230017304026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,25]],"date-time":"2018-08-25T03:25:23Z","timestamp":1535167523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230017304026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":40,"alternative-id":["S0273230017304026"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2017.12.015","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Carcinogenicity assessment of the Hedgehog pathway inhibitor, vismodegib in Tg.rasH2 mice and Sprague-Dawley rats","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2017.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}